Previous 10 | Next 10 |
Chinese biotech companies listed on U.S. financial markets are trading lower in the pre-market amid reports that the Biden administration is weighing tougher sanctions on China’s largest chipmaker, Semiconductor Manufacturing International Corp. (OTCQX:SMICY). A meeting scheduled for T...
Legend Biotech (NASDAQ:LEGN) trades 2.4% down after hours on announcing its intention to offer and sell $300M of ADSs, each representing two ordinary shares, in an underwritten public offering. Underwriters granted 30-day option to purchase up to an additional $45M of ADSs sold...
Legend Biotech Corporation (NASDAQ: LEGN) (“Legend Biotech”), a global clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, today announced that it intends to offer and sell $300.0 mil...
Updated CARTITUDE-1 data presented at ASH 2021 demonstrate a 98 percent overall response rate and 83 percent stringent complete response rate after nearly two years of follow-up CARTITUDE-1 study data also reported 2-year progression-free survival and overall survival rates we...
Legend Biotech (LEGN +10.5%) has gained more than a tenth in value, recording the biggest intraday gain since May after announcing the submission of the marketing application in Japan for its chimeric antigen receptor (CAR)-T cell therapy cilta-cel in multiple myeloma. With the New Drug Appli...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, today announced that it will host a hybrid event featuring key opinion leaders (KOLs) in multiple myeloma on Monday, December 13 at 8p...
Legend Biotech requests that their press release NewsItemId: 20211206005107 “Legend Biotech Announces Submission of New Drug Application to Japanese Regulatory Authority for BCMA CAR-T Therapy Cilta-cel for the Treatment of Relapsed or Refractory Multiple Myeloma by Janss...
Submission based on data from pivotal CARTITUDE-1 trial Legend Biotech Corporation (NASDAQ: LEGN), a global, clinical-stage biotechnology company developing and manufacturing novel therapies, announced today the submission of a New Drug Application (NDA) to the Japanese Mini...
Legend Biotech (NASDAQ:LEGN): Q3 GAAP EPS of -$0.43 misses by $0.08. Revenue of $16.82M (+43.3% Y/Y) beats by $8.99M. Shares +5.88% PM. Press Release For further details see: Legend Biotech EPS misses by $0.08, beats on revenue
Enrollment of the Phase 3 CARTITUDE-4 study evaluating ciltacabtagene autoleucel (cilta-cel) for multiple myeloma patients with 1-3 prior lines of therapy was completed by Janssen Biotech, Inc. U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...